Serum Myonectin and Adropin Levels in Predicting Diabetes

Abstract

Introduction: Myonectin is a myokine associated with type 2 diabetes mellitus and insulin resistance, and adropin is a peptide hormone that prevents IR and impaired glucose tolerance. Adropin is produced by the liver and regulates energy homeostasis. This research aimed to examine the serum levels of myonectin and adropin levels among prediabetes, newly-diagnosed type 2 diabetes mellitus, and healthy controls. Methods: For this cross-sectional study, a total of 167 individuals were divided into 3 subgroups using OGTT and HbA1c; 61 prediabetes (36.5%), 62 nT2DM (37.1%), and 44 healthy controls (26.3%). Serum levels of myonectin and adropin were assayed using enzyme-linked immunoassay kits. The anthropometric (age, gender, weight, height, waist/hip ratio -WHR-, waist and hip circumference, and body mass index -BMI-) and biochemistry findings of the participants were evaluated between the groups. Results: Our study showed that myonectin levels are associated with nT2DM and WHR (p = 0.028 and p = 0.015, respectively). The serum levels of myonectin are significantly correlated with systolic blood pressure values in the prediabetes group (p = 0.017). Linear regression analysis revealed that nT2DM affects the serum levels of myonectin, but not adropin values. The adropin levels are correlated with LDL-cholesterol, total cholesterol, and triglyceride levels in the nT2DM group (p = 0.002, p= 0.004, and p = 0.035, respectively). Conclusion: The findings of the previous studies are supported by those of this study and indicated that the serum levels of myonectin may be associated with newly-diagnosed T2DM patients. Serum myonectin levels could be a valuable marker for predicting diabetes mellitus.